SAN FRANCISCO, August 06, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ...

All three trials in the Company’s registrational ECLIPSE program for chronic hepatitis delta (CHD) have now been initiated.

Citing “ongoing funding changes,” the U of Iowa will end the Iowa Youth Writing Project and the Iowa Summer Writing Festival at the end of 2025 ...

ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD).

You will be part of the Embedded Systems Innovation (ESI) research group, specializing in model-based system engineering. In this role, you will research, develop, and apply state-of-the-art ...